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thousands of implants have been used to treat patients
with AAA.11,12
After reviewing the results of multicenter trials com-
paring endovascular grafting to open surgical treatment at
1 year, the Food and Drug Administration (FDA)
approved the use of two devices in the United States in
September 1999. This stimulated a rapid increase in
endovascular aneurysm treatment before long-term dura-
bility results were available. The purpose of this study is to
analyze longer-term results of one of these devices, a uni-
body bifurcated endovascular graft, with specific attention
to the parameters that favored endovascular repair in ear-
lier analysis.
METHODS
Previous publications have included detailed descrip-
tions of the multicenter trials evaluating the safety and effi-
cacy of the Ancure bifurcated endograft (AB) (Guidant
Endovascular Solutions, Menlo Park, Calif).2,13 Briefly,
this trial was an FDA-approved prospective evaluation of
the safety and efficacy of the bifurcated Ancure device in
the treatment of AAA. At 18 medical centers 268 patients
were enrolled during both phase I and phase II trials, from
November 22, 1995, to February 12, 1998. Patients with
suitable anatomy and considered to be acceptable surgical
candidates were enrolled after signing a research informed
Endovascular repair of abdominal aortic aneurysms
(AAA) has demonstrated benefits compared with open
repair in short-term follow-up, including more rapid
recovery, reduced blood loss, and fewer complications.1-3
However, less is known about the later outcome of
patients treated with this new approach, and concerns
about the durability of these benefits are heightened by
several reports of late complications.4-7 In addition, confi-
dence in the integrity of aortic implants over time has been
shaken by reports of migration, fabric tears, distortion,
metal fatigue, and fractures.8-10 Some of these have
plagued early designs, whereas others are discovered after
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Objective: Late complications and graft failures have recently cast serious doubts on the durability of endovascular repair
of abdominal aortic aneurysms (AAA). The results of a multicenter trial comparing a bifurcated endograft (AB) with
standard open repair (OR) were reviewed to assess the late findings of both methods of AAA treatment.
Patients and Methods: In a multicenter study of AB versus OR conducted from December 1995 to February 1998, 242
patients with AAA successfully treated with an AB and 111 control patients treated concurrently with OR were fol-
lowed up at least yearly. Twenty-five immediate conversions were excluded from late follow-up. All imaging modalities
obtained during follow-up were reviewed by a core laboratory for AAA size, endoleaks, migration, and device integrity.
Clinical outcomes at the yearly visits were compared. All death reports were reviewed to classify the cause of death.
Results: Average follow-up for the AB group was 36 months, with 194 patients at 3 years and 55 patients at 4 years. The
cumulative mortality rate was similar between the AB (15.7%) and OR groups (12.6%; P = .59). The significant early
benefit to the AB group in cardiopulmonary complications was no longer evident by 3 years. However, the AB advan-
tage in total and bowel complications, as well as the higher renal complication rates, persisted. At 3 years, 73.7% of
patients showed a significant reduction of their AAA size, whereas 25.7% still had an endoleak. One migration and two
single hook fractures were noted. Graftrelated reinterventions were performed in 50 patients (20%) without any deaths.
Twenty-eight patients (11.6%) underwent interventions for limb flow compromise, whereas 25 were treated for
endoleak. Late conversion to OR was required in five patients (2%). No AAA ruptures were encountered in either group.
Conclusions: Rupture-free survival rates after treatment of AAA with the bifurcated AB are similar to those of the OR
group. Notably the proximal attachment system is relatively stable and the AAA shrinks in three of four patients
treated. Reinterventions are nonetheless required in nearly one of five patients. Although most late procedures are per-
cutaneous, counseling regarding possible future interventions is necessary. (J Vasc Surg 2002;35:203-10.)
consent form approved by each institutional review board.
Of those patients, 242 underwent successful implantation
and form the cohort for this long-term study. Twenty-five
immediate conversions and one aborted procedure were
excluded because they provide no long-term AB data. The
group that underwent successful implantation was com-
pared with 111 control patients who underwent standard
open repair (OR). These patients were concurrently
enrolled in a sister trial on the basis of anatomy, which
excluded them from endovascular treatment with a tube
endograft. Most of these control subjects would have
qualified for the bifurcated graft had it been available a few
months earlier at all investigational sites.
Only successfully implanted AB from phases I and II
were selected for this study of long-term results to provide
the longest follow-up available. Specifically, phase III
patients enrolled later, of whom 80 were included in the
premarket approval supplement, were excluded, avoiding
dilution by analysis of patients with more limited follow-
up. It thus includes the undiluted initial “learning” expe-
rience of many investigative sites. This follow-up is
therefore not an “intent-to-treat analysis” of patients
enrolled in the trial.
Patients were followed up at 1, 6, and 12 months and
annually thereafter. A central core laboratory reviewed all
imaging studies. Abdominal radiographs, duplex scans
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Fig 1. Complication-free survival curves for both AB and OR groups over 4 years. A, Mortality. B, IDE composite. C, Cardiac. 
D, Pulmonary. E, Renal. F, Bowel.
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(US), and computed tomography scans (CT) were
inspected for device integrity, migration, size changes, and
endoleaks. Although investigators also provided their
assessment of the same end points, only the core laboratory
data were used for this study. The most recent compilation
of core laboratory data was from August 2000 and includes
mostly 3-year follow-up data. Clinical end points were
derived from case report forms filled out by the investigat-
ing teams and reviewed for accuracy by outside monitors
on the basis of source documents. The most recent compi-
lation of this data was performed in March 2001 and con-
tains 4-year follow-up data. An average time lag of nearly 6
months exists between the actual visits and the final inclu-
sion of the monitored case report form into the clinical
data. An additional lag time exists for the transmission of
imaging data to the core laboratory and their review and
inclusion in the imaging report. The authors were provided
access to all desired case report forms on file with the spon-
sor. All death reports were reviewed by the authors to
ascertain the cause of death as much as possible.
Definitions. Clinical adverse events were defined as
those detected without the use of imaging. These included
death, as well as cardiac, pulmonary, renal, bowel, and
investigative device exemption (IDE) composite events.
Definition of the IDE composite measure, which is a
reflection of all complications, including wound, hemor-
rhage, and other adverse events not previously mentioned,
was fully described previously.2 This composite safety
index included various precise thresholds that defined
moderate and severe adverse events. Graft-related reinter-
ventions for the AB group were also calculated at various
time intervals and classified as related to limb compromise,
endoleak treatment, or others. Unfortunately, reinterven-
tions in the control group were not properly captured by
the review and are not available for comparison.
The minor axis of the largest axial CT slice was con-
sidered to be the diameter of the aneurysm for size mea-
surement. This measure is closer to the true diameter of
the aneurysm in the line of flow and less influenced by tor-
tuosity. A minimum of 5 mm change from baseline was
considered to be significant for either a decrease or
increase in size. Migration was assessed by the distance of
the first axial CT slice containing half of the proximal
attachment system to the most caudal renal artery. A
movement of two or more slices was considered signifi-
cant. The presence and source of endoleaks were classified
by the core laboratory from CT and US data at all time
intervals according to the standard classification.14
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Statistics. Clinical end points of death and various
other adverse events were compared between the AB and
OR groups by use of the life-table method and were
expressed as freedom from a particular complication. The
log rank test was used to determine significance of the dif-
ference between groups. P < .05 was considered to be sig-
nificant.
RESULTS
Clinical data
Mean clinical follow-up for the 242 patients in the AB
cohort was 36 months. Data were available at 3 years for
194 patients and at 4 years for 55 patients. Of 111 control
patients, 83 completed 3-year and 67 completed 4-year
follow-up visits. 
Adverse events
No ruptures were detected in either group. The
cumulative proportion of patients experiencing various
adverse events is presented in Table I. The time course of
these events is presented by life-table method as freedom
from each adverse event in Fig 1. By this method, each
patient is counted once even if he or she experiences more
than one event. 
There was no difference in rupture-free survival
between the AB and OR groups. The survival curves are
nearly identical (P = .59). Causes of death were also simi-
lar and are listed in Table II. They indicate a preponder-
ance of chronic illnesses among the groups typical of the
usual patient population with AAA. Cardiovascular prob-
lems resulted in the largest number of deaths. Few patients
underwent an autopsy, and the cause of death was usually
surmised from the report of treating physicians. None of
Table II. Causes of death in both AB and OR groups
Cause of death AB (n = 242) OR (n = 111)
Coronary artery disease 15 5
Pulmonary 9 4
Thoracic rupture or dissection 2 1
Cancer 6 3
Cirrhosis 1 0
Stroke 0 1
Multisystem failure 2 0
Kidney failure 2 0
Unknown 1 0
TOTAL 38 14
Autopsies 3 1
Table I. Cumulative adverse event rate (with 95% confidence intervals) over 4 years in both AB and OR groups
Mortality IDE composite Cardiac Pulmonary Renal Bowel
AB (n = 242) 15.7% 51.6% 31.0% 21.5% 14.9% 2.9%
(11.1-20.3) (45.4 - 57.9) (25.2-36.8) (16.3-26.7) (10.4-19.4) (0.8-5.0)
OR (n = 111) 12.6% 60.4% 27.0% 27.0% 4.5% 10.8%
(6.4-18.8) (51.3-69.5) (18.8-35.3) (18.8-35.3) (0.7-8.4) (5.0-16.6)
the AB deaths were suspicious for aneurysm rupture,
although the possibility cannot be excluded with certainty.
Many of the early advantages of reduced major cardiac and
pulmonary morbidity with AB were no longer evident
during late follow-up by the life-table method. Ultimately,
as late problems occurred, the percentage of patients in
the AB group experiencing cardiac complications became
similar in frequency to the OR group by 1 year, and pul-
monary complications by 3 years. Renal complications,
however, remained more frequent in the AB group
throughout, whereas bowel complications were more
likely to occur among patients in the OR group. In total,
adverse events as represented by the IDE composite index
continued to be slightly in favor of the endovascular group
for the entire period of observation (P = .02).
Reinterventions
Fifty patients in the AB group underwent reinterven-
tions related to the graft implantation from 1 day to 37
months after operation. Most interventions were early in
the first year and decreased significantly over time as
depicted by the life-table method as freedom from rein-
tervention in Fig 2. Thirty-four patients (68%) under-
went intervention in the first 12 months. Twenty-eight
subjects underwent 30 reinterventions for treatment of
reduced limb flow and are the subject of a separate pub-
lication. Twenty-five underwent 33 interventions for
treatment of endoleaks, varying from percutaneous
embolization procedures to open conversion. Six patients
were in both groups. Three additional patients under-
went an intervention such as an explantation for graft
infection, a placement of a covered stent to treat an aor-
torenal vein fistula, and a complicated revascularization
for thromboembolic problems of the lower extremity in a
patient with peripheral vascular disease. No deaths were
associated with the interventions, and only one limb loss
was described in the last patient. Eighty percent of the 66
interventions were endovascular: 51 were percutaneous,
and an additional 2 used a small incision.
There were five explantations and late conversions to
open repair (2.1%) from 5 to 37 months after the initial
procedure. Three were for persistent endoleak with
enlargement of the aneurysm. An explantation with bilat-
eral axillofemoral grafts was performed for a graft infec-
tion. The patient had a chemotherapy port infection and a
septic knee before the graft infection. The last conversion
was partial, leaving the proximal attachment system in
place because of firm adherence to the aortic wall. This
conversion was performed for thromboocclusive disease of
the iliac arteries and the graft limbs. 
Imaging data
Endoleaks. The rates and sources of endoleaks at vari-
ous time intervals are presented in Fig 3. Type I endoleaks
were rare at all time intervals, and none were detected at
the 3-year follow-up, most likely as a result of therapeutic
interventions. However, it is of note that 25.7% of patients
still harbored some degree of endoleak by 3 years, mostly
of the type II variety.
Change in aneurysm size. The typical reduction in
size of the aneurysmal sac over time is illustrated in Fig 4.
The proportion of patients who demonstrated a significant
reduction in the size of their aneurysm at various time
intervals is presented in Fig 5. Of note is that nearly three
of four patients will exhibit a significant size reduction of
at least 5 mm in the aneurysmal sac by 3 years. Increase in
size was also noted in three patients at 1 year, two patients
at 2 years, and three patients at 3 years. Only one patient
exhibited an increase in size at 1 year without a demon-
strable endoleak. The others were associated with an
endoleak. No consistent relationship between the presence
of an endoleak and aneurysm size was noted. Nearly 35%
of all patients with endoleaks were noted to have signifi-
cant reduction in aneurysm size at all time periods.
Device integrity. No device failures were noted in the
3-year core laboratory report used for this study.
However, two patients were identified at a later date with
a single hook fracture each at their 3-year follow-up imag-
ing review. These two patients have been reported sepa-
rately.15 An illustration of one patient is presented in Fig
6. No clinical untoward effects have been noted so far in
these two patients. The aneurysms are shrinking.
Migration. Proximal active hook fixation is one of the
hallmarks of the Ancure bifurcated endograft. The proxi-
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Fig 2. Freedom from reintervention curve for AB group over 4
years. Fig 3. Endoleak rate and source for AB group at 12, 24, and 36
months.
mal attachment system was noted to be very stable in all
but one patient. Fig 7 illustrates a typical case with stable
position of the proximal hooks. Fig 8 depicts the only
known migration of the proximal attachment system. The
patient was treated in February 1997 after a coil emboliza-
tion of the inferior mesenteric artery. The migration was
noted at 12 and 24 months follow-up and was at least 1
cm. No endoleaks were noted on both occasions. A type I
endoleak developed at 3 years, and the aneurysm enlarged
at 4 years. The patient is being evaluated for possible con-
version or endovascular salvage. Both the first author
(MSM) and the present principal investigator at the site
independently reviewed the sizing of the aneurysm neck on
the preoperative CT scan. Both measurements agreed that
12 mm below the renal artery the neck was 28 mm and
enlarged further to 30 mm on the next axial slice 6 mm
caudad. These measurements should have excluded the
patient from endovascular treatment, but the original mea-
surements probably underestimated the size of the neck.
DISCUSSION
The application of endovascular treatment methods to
AAA repair has increased sharply in the United States since
FDA approval of two devices in September 1999.
Estimates of implants exceed 12,000 in this short time
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period.13,16 The quick acceptance of this new technology
is unprecedented and has been fueled by the attractiveness
of a less-invasive intervention and reports of lower mor-
bidity rates and faster postoperative recovery. Multiple
reports of late complications, usually arising 2 to 4 years
after implantation have done little to dampen the enthusi-
asm for this form of treatment.4,8-11 Recognizing that
endografts are different in design and performance, this
study sought to analyze the late outcomes of one of the
approved devices 5 years after it was first introduced for
clinical trials.
The late events of a cohort enrolled in a prospective
multicenter trial were reviewed. The choice of the cohort
deliberately targeted the earliest patients entered to have
the longest follow-up available. Only patients successfully
treated in phases I and II were included. Restricting the
study to these patients prevented diluting the review with
a large number of patients with limited follow-up. The
cohort in question obviously includes all “learning curve”
patients of many centers being introduced to a rather
complex deployment of a unibody bifurcated graft. The
results would be obviously tilted toward more untoward
events. The control group in this study was enrolled as
part of the slightly earlier tube trial, with the most com-
mon exclusion being the absence of a good distal neck of
Fig 4. Patient with AB endograft shows reduction in aneurysm size at 12, 24, and 36 months.
the aneurysm. This was the design of the FDA-approved
protocol but is actually quite appropriate because this sur-
gical group is closer anatomically to the AB group than to
the tube cohort.
The main purpose of AAA treatment is to avoid rup-
ture and the associated morbidity and death. It was grati-
fying to find that the Ancure bifurcated system achieved
that goal for at least the first 4 years after treatment with-
out any ruptures reported so far. Although this seemed a
foregone conclusion 5 years ago, it is no longer taken for
granted, with many reports of aneurysm rupture occur-
ring after AAA treatment with a variety of devices.4-6 The
unique performance of the Ancure bifurcated system in
that regard is difficult to explain because the rate of
endoleaks is definitely not lower than other devices.
Actually nearly 1 in 4 patients still harbored an endoleak at
3 years, although none of them were classified by the core
lab as type I. The high residual endoleak rate is most likely
related to a watchful attitude among investigators in the
face of stable or shrinking aneurysms. Because very few
aneurysms have shown any expansion even in the face of
an endoleak, a period of observation may actually be justi-
fied. Nonetheless, treatment of endoleaks remains proba-
bly a wise course of action and has been shown to be quite
effective with the Ancure system.17
A more effective seal at the proximal attachment sys-
tem may be responsible for the low rupture rate and high
rate of sac shrinkage. The low radial force allows for mod-
eling of the proximal frame to the anatomy of the neck,
and the active fixation prevents migration distally.
Obviously enlargement of the proximal neck might
threaten this stability.18,19 One case of migration is
reported here, but review of the preoperative CT indicates
that this patient was not an appropriate anatomic candi-
date for the AB device. Even assuming a proper indication,
the rate of migration in this series is far lower than other
reports in the literature.20,21 This finding argues strongly
in favor of active fixation of the endograft to the aortic
wall. The proximal attachment system of the Ancure is key
to its stability, and the performance so far at 3 to 4 years
seems to be reassuring. A word of caution should, how-
ever, be voiced at this time with the discovery of two sin-
gle hook fractures at 3 years. These were not noted on the
official radiology report of radiographs at the investigative
site. They were picked up at the core laboratory reading
later. This reconfirms that a very careful lifelong follow-
up, with particular attention to all metallic components of
endografts is essential in the management of patients with
AAA who are treated by this method. 
A significant size reduction in the size of the
excluded aneurysm is usually comforting because it
implies a significant reduction of pressure in the
aneurysm sac. The AB endograft is associated with a high
degree of shrinkage that is more pronounced than other
devices.5 The reason for this is again difficult to explain,
especially in the presence of a significant number of type
II endoleaks at 3 years. The pulsatility of a nonsupported
body may be partially responsible for a faster resorption
of thrombus from the sac, allowing for a collapse of the
aneurysm wall. On the other hand, sac shrinkage has
been associated with late adverse events such as modular
disconnection and kinking.8 This has not proven to be of
any major consequence in the unsupported unibody
design of the AB endograft.
Comparing the AB group with the OR group was also
reassuring in finding a nearly identical survival curve for
both cohorts. Review of the causes of death in both
groups show that many patients have serious comorbidites
similar to other long-term follow-up studies in the litera-
ture. An interesting observation of this analysis is that early
reductions in overall morbidity rates after endovascular
repair become less significant over a longer period of fol-
low-up. Although bowel complications remain lower with
AB, the persistent increase in renal problems and the
equalization in late cardiac and pulmonary complications
reduce the morbidity benefit of endovascular treatment
over time. This convergence may be attributed to selection
bias in this nonrandomized study, but it may also reflect a
more limited value of this method of AAA management.
Specifically, endovascular repair may be associated with
fewer perioperative complications, but this benefit is small
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Fig 5. Proportion of patients with aneurysm shrinkage at 12, 24,
and 36 months. Fig 6. Single hook fracture noted 3 years after AB endograft
implantation.
compared to ongoing serious health problems in this
patient group.
Graft-related reintervention has been a major draw-
back for endovascular treatment. In the AB group, one of
five patients required some form of intervention during
the follow-up period to correct either endoleak or limb
flow compromise. This rate is actually quite similar to
many reports in the literature.5,22 Although 80% of the
interventions were endovascular in nature and mostly per-
cutaneous, they do represent additional opportunities for
complications and add to the financial burden of this tech-
nology. Both lifelong surveillance and reinterventions are
costly and add more financial disincentive to its use. 
In conclusion, endovascular repair of AAA with the
Ancure bifurcated graft results in rupture-free survival that
is very similar to open surgical repair. Notably, the proxi-
mal attachment system is stable, and the AAA shrinks in
three of four patients treated. Nonetheless, reinterven-
tions were required in one of five patients. Although most
late procedures were percutaneous, counseling regarding
possible future interventions is necessary prior to treat-
ment. Evidence of metal fatigue in two patients should
JOURNAL OF VASCULAR SURGERY
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dictate caution in advocating endovascular treatment to
young patients at good risk.
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reviewing CT scans.
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Dr Patrick J. Lamparello (New York, NY). My question
relates to the hook fractures. Since the redesign, is this the first
time that the hook fractures have been reported?
Dr Michel S. Makaroun. Yes, these are with the new design.
None of these patients are from the previous design.
Dr Lamparello. And then my second question relates to the
infection. Can you give us more details about the case that you
had to explant for infection?
Dr Makaroun. That particular patient had hemochromatosis
and had a port implanted for chemotherapy. The port got
infected. Secondarily the patient had a septic knee. And the third
site of infection was noted around the graft in the aneurysm sac.
It was explanted and an ax-bifem was performed.
Dr M. Ashraf Mansour (Maywood, Ill). When you had that
device migration, the hooks weren’t embedded properly, do you
think, or is that like a design flaw or calcium in the wall?
Dr Makaroun. On two independent reviews, we believe it was
an improper sizing of the neck at the time of the implantation.
Again, this is in retrospect. We believe the neck was 28 mm and
a 26-mm graft was implanted.
Dr Jeffrey P. Carpenter (Philadelphia, Penn). My question
relates to the one in four patients in whom we’re not seeing
aneurysm sac shrinkage. Should we be worried about them, par-
ticularly with reports of even patients with shrinking aneurysms
having late ruptures?
Dr Makaroun. Actually, this is probably the highest reported
incidence of sac shrinkage that I’m aware of. Most patients
treated with endografts in most series do not seem to shrink all
that much even if you treat the endoleaks.
The patients that were expanding were all treated except for
one patient that was only noted to be larger at 1 year and did not
enlarge further and did not have an endoleak. Most of the others
either had their endoleaks treated and they shrunk subsequently
or have been essentially stable over time without any change in
their diameter.
Dr Luis A. Queral (Baltimore, Md). I’m concerned about
your, if I understood it correctly, 10% incidence of limb throm-
bosis over the period of time of the study. It’s my understanding
that a lot of people who use this device have resorted to stenting
during the original deposition of the graft. For this reason I’m
wondering if your incidence of limb thrombosis is with concomi-
tant stenting or is stenting done later after a thrombectomy is per-
formed?
Dr Makaroun. First, I want to maybe clarify that these were
not thromboses. The 28 interventions were for any flow abnor-
malities including just a kinking of the limb corrected by the
placement of a stent. Actually the rate of thrombosis is far lower
than this.
Almost all of these patients have been implanted prior to
February of 1998, prior to realization of how important is the
support of some of these limbs. So I would suspect that later on
the incidence of limb problems would go down if the later
cohorts were analyzed. This will be subject of an entirely differ-
ent paper that just came out from a presentation by Ron Fairman
at the SCVS this year.
Dr William J. Quiñones-Baldrich (Los Angeles, Calif). I
congratulate the authors on an excellent study. I have two ques-
tions. Of the 74% of the patients having shrinkage of their
aneurysm sac, how many have an endoleak that has not been
treated? How many patients that have the same aneurysm size on
follow-up have an endoleak? Could you give us a correlation
between presence and absence of an endoleak and the behavior or
the aneurysm as far as size?
Dr Makaroun. These data were presented yesterday at the
PVS, and the correlation is not definitely one on one. Of the
patients who do have an endoleak, about half of them are shrink-
ing with the presence of an endoleak in place. The patients who
do not have an endoleak had a higher rate of shrinkage. There are
also patients with no endoleaks and no shrinkage as well. So there
is really no close correlation between the two in this study so far.
Dr Jack L. Cronenwett (Lebanon, NH). You indicated that
you excluded early conversions and early deaths, and yet you
compared the mortality between these groups. Could you could
tell us why you chose to do the analysis in a way that would seem
to favorably dispose it toward the endograft group?
Dr Makaroun. The group that was studied, the intent was to
find long-term problems with the endografts. And the early con-
versions, obviously, do not have an endograft to follow. For the
mortality analysis, it will go up because, if I’m correct, 2 of the 26
did die. But it will still be nonsignificant when you compare the
two curves.
DISCUSSION
